← Back to homeTeva Lifts Its 2026 Revenue Forecast on Strong Austedo and Ajovy Sales
The drugmaker raised sales outlooks for three branded medicines, even as generics revenue fell and total quarterly sales slipped 2%.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources Brief
Teva Pharmaceutical reported third-quarter revenue of $4.395 billion on Tuesday, Nov. 3, down 2% from a…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
2 sources behind this story.
By NewsPlain Editorial Team · Published
About this story
We haven’t published a correction to this story.
How NewsPlain works ← Back to home